vs
Side-by-side financial comparison of BillionToOne, Inc. (BLLN) and PagerDuty, Inc. (PD). Click either name above to swap in a different company.
PagerDuty, Inc. is the larger business by last-quarter revenue ($124.5M vs $83.5M, roughly 1.5× BillionToOne, Inc.). PagerDuty, Inc. runs the higher net margin — 129.7% vs 6.8%, a 122.9% gap on every dollar of revenue. On growth, BillionToOne, Inc. posted the faster year-over-year revenue change (117.4% vs 4.7%). PagerDuty, Inc. produced more free cash flow last quarter ($24.1M vs $6.5M).
BillionToOne, Inc. is a life sciences and molecular diagnostics firm developing high-precision genetic testing solutions. Its core offerings include non-invasive prenatal tests, oncology diagnostics, and rare disease screening, serving clinical providers and patients mainly in North America.
PagerDuty, Inc. is an American cloud computing company specializing in a SaaS incident management platform for IT operations departments.
BLLN vs PD — Head-to-Head
Income Statement — Q3 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $83.5M | $124.5M |
| Net Profit | $5.7M | $161.6M |
| Gross Margin | 69.9% | 85.3% |
| Operating Margin | 11.5% | 6.5% |
| Net Margin | 6.8% | 129.7% |
| Revenue YoY | 117.4% | 4.7% |
| Net Profit YoY | 138.3% | 2827.7% |
| EPS (diluted) | $0.10 | $1.69 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $124.5M | ||
| Q3 25 | $83.5M | $123.4M | ||
| Q2 25 | — | $119.8M | ||
| Q1 25 | — | $121.4M | ||
| Q4 24 | — | $118.9M | ||
| Q3 24 | $38.4M | $115.9M | ||
| Q2 24 | — | $111.2M | ||
| Q1 24 | — | $111.1M |
| Q4 25 | — | $161.6M | ||
| Q3 25 | $5.7M | $9.6M | ||
| Q2 25 | — | $-7.2M | ||
| Q1 25 | — | $-8.8M | ||
| Q4 24 | — | $-5.9M | ||
| Q3 24 | $-14.9M | $-10.9M | ||
| Q2 24 | — | $-17.1M | ||
| Q1 24 | — | $-28.2M |
| Q4 25 | — | 85.3% | ||
| Q3 25 | 69.9% | 84.6% | ||
| Q2 25 | — | 84.0% | ||
| Q1 25 | — | 83.6% | ||
| Q4 24 | — | 83.0% | ||
| Q3 24 | 52.6% | 82.7% | ||
| Q2 24 | — | 82.6% | ||
| Q1 24 | — | 81.7% |
| Q4 25 | — | 6.5% | ||
| Q3 25 | 11.5% | 2.9% | ||
| Q2 25 | — | -8.6% | ||
| Q1 25 | — | -9.6% | ||
| Q4 24 | — | -8.7% | ||
| Q3 24 | -32.9% | -13.8% | ||
| Q2 24 | — | -19.5% | ||
| Q1 24 | — | -30.1% |
| Q4 25 | — | 129.7% | ||
| Q3 25 | 6.8% | 7.8% | ||
| Q2 25 | — | -6.0% | ||
| Q1 25 | — | -7.2% | ||
| Q4 24 | — | -5.0% | ||
| Q3 24 | -38.8% | -9.4% | ||
| Q2 24 | — | -15.4% | ||
| Q1 24 | — | -25.3% |
| Q4 25 | — | $1.69 | ||
| Q3 25 | $0.10 | $0.10 | ||
| Q2 25 | — | $-0.07 | ||
| Q1 25 | — | $-0.12 | ||
| Q4 24 | — | $-0.07 | ||
| Q3 24 | $-1.47 | $-0.14 | ||
| Q2 24 | — | $-0.26 | ||
| Q1 24 | — | $-0.34 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $195.2M | $547.8M |
| Total DebtLower is stronger | $55.0M | — |
| Stockholders' EquityBook value | $-239.5M | $320.5M |
| Total Assets | $327.5M | $1.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $547.8M | ||
| Q3 25 | $195.2M | $567.9M | ||
| Q2 25 | — | $597.1M | ||
| Q1 25 | — | $570.8M | ||
| Q4 24 | — | $542.2M | ||
| Q3 24 | — | $599.3M | ||
| Q2 24 | — | $592.8M | ||
| Q1 24 | — | $571.2M |
| Q4 25 | — | — | ||
| Q3 25 | $55.0M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $484.5M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $489.5M |
| Q4 25 | — | $320.5M | ||
| Q3 25 | $-239.5M | $180.7M | ||
| Q2 25 | — | $145.7M | ||
| Q1 25 | — | $129.8M | ||
| Q4 24 | — | $111.6M | ||
| Q3 24 | $-242.9M | $164.7M | ||
| Q2 24 | — | $174.0M | ||
| Q1 24 | — | $171.6M |
| Q4 25 | — | $1.0B | ||
| Q3 25 | $327.5M | $891.5M | ||
| Q2 25 | — | $926.8M | ||
| Q1 25 | — | $927.3M | ||
| Q4 24 | — | $866.8M | ||
| Q3 24 | — | $916.0M | ||
| Q2 24 | — | $924.0M | ||
| Q1 24 | — | $925.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 3.73× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 2.85× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $13.8M | $24.8M |
| Free Cash FlowOCF − Capex | $6.5M | $24.1M |
| FCF MarginFCF / Revenue | 7.7% | 19.3% |
| Capex IntensityCapex / Revenue | 8.8% | 0.6% |
| Cash ConversionOCF / Net Profit | 2.42× | 0.15× |
| TTM Free Cash FlowTrailing 4 quarters | — | $117.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $24.8M | ||
| Q3 25 | $13.8M | $34.0M | ||
| Q2 25 | — | $30.7M | ||
| Q1 25 | — | $31.4M | ||
| Q4 24 | — | $22.1M | ||
| Q3 24 | — | $35.8M | ||
| Q2 24 | — | $28.6M | ||
| Q1 24 | — | $22.2M |
| Q4 25 | — | $24.1M | ||
| Q3 25 | $6.5M | $33.1M | ||
| Q2 25 | — | $30.2M | ||
| Q1 25 | — | $30.3M | ||
| Q4 24 | — | $21.5M | ||
| Q3 24 | — | $35.1M | ||
| Q2 24 | — | $28.2M | ||
| Q1 24 | — | $21.2M |
| Q4 25 | — | 19.3% | ||
| Q3 25 | 7.7% | 26.8% | ||
| Q2 25 | — | 25.2% | ||
| Q1 25 | — | 24.9% | ||
| Q4 24 | — | 18.1% | ||
| Q3 24 | — | 30.3% | ||
| Q2 24 | — | 25.4% | ||
| Q1 24 | — | 19.1% |
| Q4 25 | — | 0.6% | ||
| Q3 25 | 8.8% | 0.7% | ||
| Q2 25 | — | 0.4% | ||
| Q1 25 | — | 0.9% | ||
| Q4 24 | — | 0.5% | ||
| Q3 24 | — | 0.5% | ||
| Q2 24 | — | 0.4% | ||
| Q1 24 | — | 0.9% |
| Q4 25 | — | 0.15× | ||
| Q3 25 | 2.42× | 3.55× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BLLN
| Prenatal | $74.1M | 89% |
| Oncology | $8.7M | 10% |
PD
| US | $88.8M | 71% |
| Non Us | $35.7M | 29% |
